Published reports of clinical trials of psychiatric drugs typically include a graphic showing the efficacy of the study drug in reducing symptoms of the disorder compared with placebo. The efficacy graphic that was published used the same 25-point vertical axis showing a drop in symptoms as the brexpiprazole publication did. The efficacy graphic used a 16-point vertical axis, which ramped up the magnifying effect 11-fold. The efficacy graphic in the published article used a 25-point vertical axis (a seven-fold magnification of results). In every instance, the visual picture of significant drug efficacy arose from the use of a vertical axis that served as a magnifying glass, dramatically enlarging the differences between drug and placebo.